Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer

Clinical trial NCT02066532 · COMPLETED

Trial details

NCT number: NCT02066532
Sponsor: Dawn L. Hershman
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Metastatic Breast Cancer Breast Carcinoma HER-2 Positive Breast Cancer

Start date: 2014-06-01
Primary completion: 2020-10-14
Enrollment: 32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.